DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences: The 2025 Wells Fargo Healthcare Conference on...
Business Wire·12d ago
DexCom Expands Access and Innovation While Balancing Headwinds
DXCM grows on type 2 access, Stelo adoption, and new sensor launches, but faces margin pressures, competition and leadership transition.
Zacks·18d ago
Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data
TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.
Zacks·23d ago
Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It?
ABT's Diabetes Care sales surge 19.6% in Q2, fueled by strong U.S. demand and new OTC approvals for its CGM systems.
DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.
Zacks·1mo ago
Compared to Estimates, DexCom (DXCM) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·1mo ago
DexCom (DXCM) Q2 Earnings and Revenues Top Estimates
DexCom (DXCM) delivered earnings and revenue surprises of +6.67% and +3.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
DexCom (DXCM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Besides Wall Street's top-and-bottom-line estimates for DexCom (DXCM), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.